Drug Profile

Latrepirdine - BioXcel Therapeutics

Alternative Names: BXCL 502

Latest Information Update: 24 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Inveni
Developer BioXcel Therapeutics
Class Antidementias; Behavioural disorder therapies; Indoles; Small molecules
Mechanism of Action G protein-coupled receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

24 Feb 2025 Suspended - Preclinical for Agitation in USA (unspecified route) Prior to February 2025 (BioXcel Therapeutics Pipeline, February 2025)
15 Mar 2022 Discontinued - Phase-I/II for Neurodegenerative disorders (unspecified route) before March 2022 (BioXcel Therapeutics' pipeline, March 2022)
10 Mar 2022 Preclinical trials in Agitation in USA (unspecified route) before March 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com